GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » EBITDA

LeMaitre Vascular (LeMaitre Vascular) EBITDA : $49.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is LeMaitre Vascular EBITDA?

LeMaitre Vascular's EBITDA for the three months ended in Dec. 2023 was $14.9 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $49.0 Mil.

During the past 12 months, the average EBITDA Growth Rate of LeMaitre Vascular was 32.70% per year. During the past 3 years, the average EBITDA Growth Rate was 9.70% per year. During the past 5 years, the average EBITDA Growth Rate was 9.50% per year. During the past 10 years, the average EBITDA Growth Rate was 19.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of LeMaitre Vascular was 60.50% per year. The lowest was -65.00% per year. And the median was 18.60% per year.

LeMaitre Vascular's EBITDA per Share for the three months ended in Dec. 2023 was $0.67. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.19.

During the past 12 months, the average EBITDA per Share Growth Rate of LeMaitre Vascular was 31.20% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 6.50% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 7.00% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 16.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of LeMaitre Vascular was 40.90% per year. The lowest was -67.90% per year. And the median was 16.20% per year.


LeMaitre Vascular EBITDA Historical Data

The historical data trend for LeMaitre Vascular's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular EBITDA Chart

LeMaitre Vascular Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.10 37.06 47.58 36.92 48.99

LeMaitre Vascular Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.81 10.53 11.96 11.58 14.93

Competitive Comparison of LeMaitre Vascular's EBITDA

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LeMaitre Vascular's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

LeMaitre Vascular's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

LeMaitre Vascular's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, LeMaitre Vascular's EBITDA was $49.0 Mil.

LeMaitre Vascular's EBITDA for the quarter that ended in Dec. 2023 is calculated as

LeMaitre Vascular's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, LeMaitre Vascular's EBITDA was $14.9 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $49.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

LeMaitre Vascular  (NAS:LMAT) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


LeMaitre Vascular EBITDA Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


LeMaitre Vascular (LeMaitre Vascular) Business Description

Traded in Other Exchanges
Address
63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Executives
George W Lemaitre director, 10 percent owner, officer: Chairman, President and CEO 342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush director C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski director SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts director, officer: CFO and Director 55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke officer: Senior V. P., Operations 61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr officer: Executive V.P. Finance 68 BEACON STREET, BOSTON MA 02108
Michael H Thomas director P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer officer: President, International OP AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas officer: VP of Sales, The Americas C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W director, officer: V.P., Human Resources,Director 8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays director C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden officer: VP, North American Sales 236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr director HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199